Bio-Techne Corp Stock News

Sector ETF report for PBE

The Tissue Microarray Market 2021 report provides a 360-degree survey of all sections responsible for the development of the Tissue Microarray market. The industry research explores the current fierce situation and the changing factors of the various factors that influence

The Glycobiology Market report focus on the current trends of the market along with detailed analysis which provides data regarding this market rate, and it also predicts the future market growth rate. The Glycobiology Market study includes research on the

Sumitomo Mitsui Trust Holdings Inc. reduced its position in shares of Bio-Techne Co. (NASDAQ:TECH) by 5.4% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 222,228 shares of the biotechnology companys stock after selling 12,718 shares during the period. Sumitomo []

Zacks Investment Research downgraded shares of Bio-Techne (NASDAQ:TECH) from a hold rating to a sell rating in a research report released on Wednesday, Zacks.com reports. According to Zacks, Bio-Techne Corporation is a global life sciences company. It develops, manufactures, and sells biotechnology products and clinical diagnostic controls. It provides proteins, such as cytokines, growth factors, []

Exchange Traded Concepts LLC lowered its stake in Bio-Techne Co. (NASDAQ:TECH) by 85.9% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 190 shares of the biotechnology companys stock after selling 1,153 shares during the period. Exchange Traded Concepts LLCs holdings []

Raymond James Trust N.A. lessened its position in shares of Bio-Techne Co. (NASDAQ:TECH) by 9.7% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,437 shares of the biotechnology companys stock after selling 155 shares during the quarter. Raymond James Trust N.A.s []

Legacy Capital Partners Inc. bought a new stake in Bio-Techne Co. (NASDAQ:TECH) in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 415 shares of the biotechnology companys stock, valued at approximately $201,000. Other hedge funds and other institutional investors also recently []

Ritholtz Wealth Management acquired a new stake in Bio-Techne Co. (NASDAQ:TECH) during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 505 shares of the biotechnology companys stock, valued at approximately $245,000. A number of other institutional investors have also made changes []

Wall Street analysts expect Bio-Techne Co. (NASDAQ:TECH) to announce $267.04 million in sales for the current fiscal quarter, according to Zacks. Three analysts have issued estimates for Bio-Technes earnings, with the highest sales estimate coming in at $268.70 million and the lowest estimate coming in at $263.81 million. Bio-Techne posted sales of $224.25 million during []

Equities research analysts expect Bio-Techne Co. (NASDAQ:TECH) to post $1.82 earnings per share for the current quarter, according to Zacks Investment Research. Three analysts have made estimates for Bio-Technes earnings. The highest EPS estimate is $1.87 and the lowest is $1.78. Bio-Techne reported earnings of $1.62 per share in the same quarter last year, which []

Louisiana State Employees Retirement System trimmed its stake in Bio-Techne Co. (NASDAQ:TECH) by 76.2% in the 3rd quarter, HoldingsChannel reports. The firm owned 2,400 shares of the biotechnology companys stock after selling 7,700 shares during the period. Louisiana State Employees Retirement Systems holdings in Bio-Techne were worth $1,163,000 as of its most recent filing with []